Abstract:The coronavirus papain-like protease (PLpro) is crucial for viral replicase polyprotein processing. Additionally, PLpro can subvert host defense mechanisms by its deubiquitinating (DUB) and deISGylating activities. To elucidate the role of these activities during SARS-CoV-2 infection, we introduced mutations that disrupt binding of PLpro to ubiquitin or ISG15. We identified several mutations that strongly reduced DUB activity of PLpro, without affecting viral polyprotein processing. In contrast, mutations that abrogated deISGylating activity also hampered viral polyprotein processing and when introduced into the virus these mutants were not viable. SARS-CoV-2 mutants exhibiting reduced DUB activity elicited a stronger interferon response in human lung cells. In a mouse model of severe disease, disruption of PLpro DUB activity did not affect lethality, virus replication, or innate immune responses in the lungs. This suggests that the DUB activity of SARS-CoV-2 PLpro is dispensable for virus replication and does not affect innate immune responses in vivo . Interestingly, the DUB mutant of SARS-CoV replicated to slightly lower titers in mice and elicited a diminished immune response early in infection, although lethality was unaffected. We previously showed that a MERS-CoV mutant deficient in DUB and deISGylating activity was strongly attenuated in mice. Here, we demonstrate that the role of PLpro DUB activity during infection can vary considerably between highly pathogenic coronaviruses. Therefore, careful considerations should be taken when developing pan-coronavirus antiviral strategies targeting PLpro. The COVID-19 pandemic highlighted the need for pan-coronavirus targeting antivirals and vaccines. One of the potential targets is the viral papain-like protease (PLpro). PLpro is required for processing of the viral replicase polyprotein, thus enabling virus replication, but it also contributes to immune evasion by its deubiquitinating and deISGylating activities. Here we show that the deubiquitinating activity of SARS-CoV-2 PLpro does not influence virus replication, innate immune responses or lethality in mice. For SARS-CoV, we found that a mutant virus lacking deubiquitinating activity replicated to slightly lower titers and elicited a diminished immune response. This is in strong contrast to our previous findings for MERS-CoV, where removal of the deubiquitinating and deISGylating activities of PLpro strongly attenuated the virus in mice, completely alleviating lethality, and rendered it a promising live-attenuated vaccine candidate. This study uncovers important differences between highly pathogenic coronaviruses in the differential roles of PLpro during infection. These mechanistic insights provide valuable information for the development of pan-coronavirus targeting antivirals and vaccines.

Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Potential of Coronavirus 3C-Like Protease Inhibitors for the Development of New Anti-Sars-cov-2 Drugs: Insights from Structures of Protease and Inhibitors.

Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking

Development of de-novo coronavirus 3-chymotrypsin-like protease (3CL pro ) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development

Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone

Targeting Proteases for Treating COVID-19

An update review of emerging small-molecule therapeutic options for COVID-19

Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo

An overview of potential inhibitors targeting non-structural proteins 3 (PL<SUP>pro</SUP> and Mac1) and 5 (3CL<SUP>p</SUP><SUP>ro</SUP>/M<SUP>pro</SUP>) of SARS-CoV-2

Drug Repurposing for the SARS‐CoV‐2 Papain‐Like Protease

Targeting papain-like protease for broad-spectrum coronavirus inhibition

Drug repurposing approach to combating coronavirus: Potential drugs and drug targets

Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies

Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships

Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection

Activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease with antiviral efficacy in murine infection model